Evidence map›Paper›PMID 41678112›Full record

ArticleDermatology and therapy2026

Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies.

Andrew Blauvelt, Leon Kircik, Eric L Simpson, Peter Lio, Lawrence F Eichenfield, Vimal H Prajapati, Parbeer Grewal, Charles Lynde, H Chih-Ho Hong, Daniel Sturm and 5 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03745638 phase3completednot on this map

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

TypeinterventionalSponsorIncyte CorporationRan2018 to 2020Enrolled631ConditionsAtopic DermatitisArmsRuxolitinib Cream, Vehicle Cream
NCT03745651 phase3completednot on this map

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

TypeinterventionalSponsorIncyte CorporationRan2018 to 2020Enrolled618ConditionsAtopic DermatitisArmsRuxolitinib cream, Vehicle cream
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andrew BlauveltOregon Medical Research Center, Portland, OR, USA.
Leon KircikIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Eric L SimpsonOregon Health & Science University, Portland, OR, USA.
Peter LioFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Lawrence F EichenfieldUniversity of California San Diego, 3030 Children's Way # 2, La Jolla, CA, 92123, USA.
Vimal H PrajapatiDivision of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Parbeer GrewalRejuvenation Medical, Edmonton, AB, Canada.
Charles LyndeLynde Institute for Dermatology, Markham, ON, Canada.
H Chih-Ho HongDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Daniel SturmIncyte Corporation, Wilmington, DE, USA.
Howard KallenderIncyte Corporation, Wilmington, DE, USA.
Haobo RenIncyte Corporation, Wilmington, DE, USA.
Dilan ParanagamaIncyte Corporation, Wilmington, DE, USA.
Grace K W WongIncyte Biosciences Canada, Saint-Laurent, QC, Canada.
Bob GengUniversity of California San Diego, 3030 Children's Way # 2, La Jolla, CA, 92123, USA. geng.bob@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong-term disease and symptom control is a goal of atopic dermatitis (AD) therapy. This study assessed the long-term maintenance of disease and symptom control with as-needed application of ruxolitinib cream.

methodsPatients aged ≥ 12 years with AD, an Investigator's Global Assessment (IGA) score of 2/3, and 3-20% affected body surface area were included in the phase 3 TRuE-AD1 and TRuE-AD2 studies. This analysis included patients randomized to twice-daily (BID) 1.5% ruxolitinib cream for 8 weeks and then as-needed (IGA ≥ 1) BID for up to 44 weeks (long-term safety [LTS] period).

resultsAmong patients evaluated for disease control in the as-needed period (N = 428), IGA 0/1 (skin/almost clear skin) was achieved by 67.1% of patients at week 8. From week 8, 80-90% of patients with IGA 0/1 at a given visit maintained or improved their response at the next visit. Median time to worsening disease (IGA ≥ 2) was 36.1 weeks during the as-needed period, and IGA 0/1 was quickly recaptured. Patients spent a median 43.9% of the as-needed period off treatment due to lesion clearance. No itch/no sleep disturbance (Patient-Oriented Eczema Measure questions 1 and 2) was reported in 32.7%/71.8% of patients at week 8 and 36.2%/74.5% of patients at week 52. No new safety concerns emerged in the LTS period.

conclusionContinued disease and symptom control with substantial time off treatment makes 1.5% ruxolitinib cream an effective long-term option for patients with mild to moderate AD.

trial registrationClinicaltrials.gov, NCT03745638 and NCT03745651 (studies registered November 19, 2018).

Indexed as

Atopic dermatitisItchJanus kinase inhibitorMaintenance of disease controlRuxolitinib creamSymptomsTime off treatmentTopical

Identifiers

PMID41678112
PMCPMC13013897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.